7d
Zacks Investment Research on MSNGlaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...
The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...
Fluarixâ„¢, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to assess the non-inferiority of HI antibody responses ...
Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results